Jyong Biotech Ltd. announced updates on its plant-derived drug MCS-2, highlighting its potential benefits and competitive advantages in treating benign prostatic hyperplasia (BPH). MCS-2 is the first oral botanical drug to complete global Phase III trials, conducted extensively in the U.S. and Taiwan with strong safety results and no serious adverse events. The company holds global patents for its technology, which enhances drug bioavailability and allows multiple formulations. With a large market need for safer long-term BPH treatments, Jyong Biotech aims to commercialize MCS-2 and expand into new indications, emphasizing ongoing innovation and global regulatory compliance. The drug remains investigational and not yet approved for commercial use.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
QuickLogic and PQSecure Technologies demonstrated that PQSecure's CRYSTAL-1000C post-quantum cryptographic IP can be efficiently implemented on QuickLogic's reprogrammable eFPGA fabric within SoCs. This allows field-upgradeable security without costl...
Relmada Therapeutics, a clinical-stage biotech company focused on oncology and CNS therapies, will announce its financial results for Q2 2026 on August 6, 2026. The company will host a conference call and webcast to discuss the results and recent bus...
Gilat Satellite Networks Ltd., a global leader in satellite networking technology, will release its second quarter 2026 financial results on August 5, 2026. Following the release, CEO Adi Sfadia and CFO Gil Benyamini will hold a conference call and w...
B&M European Value Retail's first-quarter update has divided analysts, with Deutsche Bank upgrading the stock to 'hold' citing stabilizing profit margins and a sensible turnaround strategy by new CEO Tjeerd Jegen. Deutsche Bank raised its profit fore...
